Results 31 to 40 of about 66,232 (237)

Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications

Journal of Immunology Research, 2016
Today, potential immunogenicity can be better evaluated during the drug development process, and we have rational approaches to manage the clinical consequences of immunogenicity.
Anshu Kuriakose, Narendra Chirmule, Pradip Nair   +2 more
doaj   +1 more source

Risk Factor Analysis for the Immunogenicity of Adalimumab Associated with Decreased Clinical Response in Chinese Patients with Psoriasis

, 2017
Although anti-drug antibodies against biologics have been associated with decreased clinical efficacy, the immunogenicity of biologics seems to vary between drugs, diseases and ethnicities.
蔡呈芳;詹智傑;邱顯鎰;林頌然, Chiu, Hsien-Yi;Wang, Ting-Shun;Chan, Chih-Chieh;Lin, Sung-Jan;Tsai, Tsen-Fang   +1 more
core   +1 more source

T cell assays for non-clinical immunogenicity risk assessment: best practices recommended by the European Immunogenicity Platform

Frontiers in Immunology
In vitro and in silico tools help drug developers reduce unwanted immunogenicity of biologics at the design stage. These include assays that examine different immune system processes leading to anti-drug antibody (ADA) or cytotoxic cellular response ...
Sophie Tourdot, Anette Christine Karle, Marc Rosenbaum, Chloé Ackaert, Pauline Le Vu, Michael Gutknecht, Maryam Ahmadi, Annelies W. Turksma, Timothy P. Hickling   +8 more
doaj   +1 more source

Epigenetic reprogramming of lineage switching in cancer

FEBS Letters, EarlyView.
Cancer cells rarely commit to a single identity. Epigenetic mechanisms and tumor microenvironment cues push epithelial cells toward flexible, hybrid states that can shift into mesenchymal, neuroendocrine, or stem‐like fates, driving metastasis, drug resistance, and tumor heterogeneity. Targeting the epigenetic regulators behind these transitions, using
Ezgi Boyvatlı, Burcu Akman, Ezgi Bağırsakçı, Nese Atabey, Serap Erkek‐Ozhan   +4 more
wiley   +1 more source

Long-term humoral and cellular immune responses following Covaxin vaccination: a 2-year prospective longitudinal study

Frontiers in Immunology
BackgroundGlobally, multiple SARS-CoV-2 vaccines received emergency authorization, primarily based on adenoviral vector, mRNA, or inactivated virus platforms.
Archana Tripathy, Archana Tripathy, Sreeparna Podder, Sreeparna Podder, Swatishree Sradhanjali, Swatishree Sradhanjali, Mamuni Swain, Debdutta Bhattacharya, Debaprasad Parai, Sanghamitra Pati, Sunil K. Raghav, Sunil K. Raghav   +11 more
doaj   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Dendritic cell maturation assay for non-clinical immunogenicity risk assessment: best practices recommended by the European Immunogenicity Platform

Frontiers in Immunology
Early assessment and mitigation of non-clinical immunogenicity risk during early drug development is key for the development of safe and efficacious therapeutics.
Chloé Ackaert, Bruno Gonzalez-Nolasco, Marc Rosenbaum, Mercedes Perez-Olivares, Michael Gutknecht, Axel Ducret, Anette Christine Karle   +6 more
doaj   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Complex immunogenicity assessment in caplacizumab-treated patients with immune-mediated thrombotic thrombocytopenic purpura who have received plasma exchange

Research and Practice in Thrombosis and Haemostasis
Background: International Society on Thrombosis and Haemostasis guidelines for immune-mediated thrombotic thrombocytopenic purpura (iTTP) treatment recommend concurrent therapeutic plasma exchange (TPE), immunosuppressive therapy (IST), and caplacizumab.
Brendy Van Butsel, Maria Laura Sargentini-Maier, Ana Paula Marques, Yana Vandenbossche, Gabriela Marcheva, Sriya Gunawardena, Samuel Pine   +6 more
doaj   +1 more source

PANoptosis in the pathogenesis of myelodysplastic syndromes

Molecular Oncology, EarlyView.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla, Jyoti Lamichhane, Cameron Lewis, Peter Breslin, Jiwang Zhang   +4 more
wiley   +1 more source